drugset / Trial / NCT06563102

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

NCT06563102

Phase 4 Completed 101 enrolled AstraZeneca Fortrea · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.

Timeline

Start
2024-09-11
Primary completion
2026-02-24
Completion
2026-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 80 ug Inhaled
Subject Salbutamol Unknown 90 ug Inhaled

Indications